Characteristics of Daratumumab Reactions in Patients Who Transitioned from Intravenous Daratumumab to Subcutaneous Daratumumab

被引：0
|
作者：
Kim, Chang Kun [1 ]
Douglass, Lindsey [1 ]
Gustafson, Beth [1 ]
Begemann, Madeline E. [2 ]
Cossor, Furha I. [3 ]
Gupta, Vinay [4 ]
Raza, Shahzad [3 ]
机构：
[1] St Lukes Hosp Kansas City, Kansas City, MO USA
[2] St Lukes Canc Inst, Kansas City, MO USA
[3] Univ Missouri Kansas City, St Lukes Hosp Kansas City, St Lukes Canc Inst, Kansas City, MO USA
[4] St Lukes Hosp Kansas City, St Lukes Canc Inst East, Lees Summit, MO USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-154174
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4744
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma
    Copley, Melissa
    Metheny, Leland
    Klisovic, Rebecca B.
    Malek, Ehsan
    [J]. BLOOD, 2022, 140 : 13202 - 13203
  • [2] Subcutaneous versus intravenous daratumumab in multiple myeloma
    Shibusawa, Motoharu
    Tanimoto, Tetsuya
    [J]. LANCET HAEMATOLOGY, 2020, 7 (08): : E558 - E558
  • [3] Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).
    Bahlis, Nizar J.
    Zonder, Jeffrey A.
    Wroblewski, Susan
    Qi, Ming
    Renaud, Thomas
    Jackson, Carolyn Chang
    Facon, Thierry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice
    Hamadeh, Issam S.
    Moore, Donald C.
    Martin, Allison
    Karabinos, Allison
    Hill, Hailey
    Ndiaye, Ami
    Robinson, Jordan D.
    Paul, Barry A.
    Atrash, Shebli
    Bhutani, Manisha
    Voorhees, Peter M.
    Usmani, Saad Z.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (07): : 470 - 475
  • [5] Subcutaneous versus intravenous daratumumab in multiple myeloma reply
    Mateos, Maria-Victoria
    Usmani, Saad Z.
    [J]. LANCET HAEMATOLOGY, 2020, 7 (08): : E559 - E559
  • [6] Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Multiple Myeloma Patients at Mayo Clinic
    Soefje, Scott
    Carpenter, Corinne
    Carlson, Katherine
    Awasthi, Samir
    Lin, Thomas S.
    Kaila, Shuchita
    Tarjan, Daniel
    Kayal, Nikhil
    Kirkup, Christian
    Wagner, Tyler
    Gray, Kathleen
    Kumar, Shaji
    [J]. BLOOD, 2021, 138
  • [7] Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers
    Cook, Gordon
    Ashcroft, John
    Fernandez, Mariana
    Henshaw, Sarah
    Khalaf, Zeyad
    Pratt, Guy
    Tailor, Anish
    Rabin, Neil
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
    Yamaoka, Kenta
    Irie, Kei
    Hiramoto, Nobuhiro
    Hirabatake, Masaki
    Ikesue, Hiroaki
    Hashida, Tohru
    Shimizu, Tadashi
    Ishikawa, Takayuki
    Muroi, Nobuyuki
    [J]. INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 761 - 767
  • [9] Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers
    Soefje, Scott A.
    Carpenter, Corinne
    Carlson, Katherine
    Awasthi, Samir
    Lin, Thomas S.
    Kaila, Shuchita
    Tarjan, Daniel
    Kayal, Nikhil
    Kirkup, Christian
    Wagner, Tyler E.
    Gray, Kathleen S.
    Kumar, Shaji
    [J]. JCO ONCOLOGY PRACTICE, 2023, 19 (04) : 208 - +
  • [10] Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
    Kenta Yamaoka
    Kei Irie
    Nobuhiro Hiramoto
    Masaki Hirabatake
    Hiroaki Ikesue
    Tohru Hashida
    Tadashi Shimizu
    Takayuki Ishikawa
    Nobuyuki Muroi
    [J]. Investigational New Drugs, 2023, 41 : 761 - 767
12345